Evaluating the effects of antibodies on HIV control in children
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana
This study is looking at whether two special antibodies can help keep HIV under control in children who have been successfully treated with medication since birth, to see if these antibodies can be a new way to manage their condition instead of the usual treatments.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard School of Public Health NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10782550 on NIH RePORTER |
What this research studies
This research investigates the use of two broadly neutralizing monoclonal antibodies, VRC01LS and 10-1074, to help maintain viral suppression in children who are HIV-1 infected and have been virally suppressed after receiving early antiretroviral therapy (ART). The trial involves children who started ART shortly after birth and assesses their clinical and immunologic responses to the antibody treatment. Participants will undergo a series of phases, including initial treatment with ART followed by dual antibody therapy, to evaluate the potential for these antibodies to replace standard ART in managing HIV in young patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are children who are HIV-1 infected, have been virally suppressed, and started ART within 96 hours of birth.
Not a fit: Patients who are not HIV-1 infected or those who did not receive early ART treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for maintaining HIV viral suppression in children without the need for continuous antiretroviral therapy.
How similar studies have performed: Previous research has shown promise in using broadly neutralizing antibodies for HIV treatment, indicating potential for success in this novel approach.
Where this research is happening
Boston, United States
- Harvard School of Public Health — Boston, United States (Active)
Researchers
- Principal investigator: Shapiro, Roger L — Harvard School of Public Health
- Study coordinator: Shapiro, Roger L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.